



Marked-up Paragraph:**RELATED APPLICATIONS**

This application is a divisional of U.S. Serial No. 09/971,682, filed May 1, 1998, now U.S. Patent No. 6,204,267, which, in turn, The present application claims priority to U.S. Serial Numbers 60/060,152, filed September 26, 1997, entitled METHODS OF MODULATING SERINE /THREONINE PROTEIN KINASE FUNCTION WITH QUINAZOLINE BASED COMPOUNDS, by Tan et al. (Lyon & Lyon Docket No. 225/284) and 60/045,351, filed May 2, 1997, entitled METHODS OF MODULATING SERINE/THREONINE PROTEIN KINASE FUNCTION WITH 5-SUBSTITUTED QUINAZOLINE COMPOUNDS, by Tang et al. (Lyon & Lyon Docket No. 223/249),, all of which are incorporated by reference herein in their entirety, including any drawings.

Marked-up Claim:

1. (Amended) A method of modulating the function of a serine/threonine protein kinase with a quinazoline-based compound substituted ~~five membered or six membered aryl or heteroaryl ring,~~ comprising the step of contacting cells expressing said serine/threonine kinase with said compound, or a pharmaceutically acceptable salt thereof, wherein said compound has the formula set forth in formula I or III:



wherein:

(a) Z is oxygen, NX₁, or sulfur, where X₁ is selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and five-membered or six-membered heteroaryl or six-membered aryl ring moieties;

(b) n is 0, 1, 2, 3, or 4;

(c) A₁, A₂, A₃, A₄ and A₅ are independently selected from the group consisting of carbon, nitrogen, oxygen, and sulfur,

provided that if any of A_1 , A_2 , A_3 , A_4 and A_5 is nitrogen, oxygen, or sulfur, said A_1 , A_2 , A_3 , A_4 and A_5 is not substituted with R_6 , R_7 , R_8 or R_9 ;

(d) R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_8 and R_9 are independently selected from the group consisting of:

(i) hydrogen;

(ii) saturated or unsaturated alkyl;

(iii) NX_2X_3 , where X_2 and X_3 are independently selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and five-membered or six-membered heteroaryl or six-membered aryl ring moieties;

(iv) halogen or trihalomethyl;

(v) a ketone of formula $-CO-X_4$, where X_4 is selected from the group consisting of hydrogen, alkyl, and five-membered or six-membered heteroaryl or six-membered aryl ring moieties;

(vi) a carboxylic acid of formula $-(X_5)_{n5}-COOH$ or ester of formula $-(X_6)_{n6}-COOX_7$, where X_5 , X_6 , and X_7 are independently selected from the group consisting of alkyl and five-membered or six-membered heteroaryl or six-membered aryl ring moieties and where $n5$ and $n6$ are each independently 0 or 1;

(vii) an alcohol of formula $-(X_8)_{n8}-OH$ or an alkoxy moiety of formula $-(X_8)_{n8}-OX_9$, where X_8 and X_9 are independently selected from the group consisting of alkyl and five-membered or six-membered heteroaryl or six-membered aryl ring moieties and where $n8$ is 0 or 1, and where said ring moieties are optionally substituted with one or more substituents selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, and ester;

(viii) $-NHCOX_{10}$, where X_{10} is selected from the group consisting of alkyl, hydroxyl, and five-membered or six-membered heteroaryl or six-membered aryl ring moieties, wherein said ring moieties are optionally substituted with one or more substituents selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, and ester;

(ix) $-SO_2NX_{11}X_{12}$, where X_{11} and X_{12} are selected from the group consisting of hydrogen, alkyl, and five-membered or six-membered heteroaryl or six-membered aryl ring moieties; and

(x) a five-membered or six-membered heteroaryl or six-membered aryl ring moiety optionally substituted with one or more substituents selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, and ester moieties;

(e) any adjacent R_3 , R_4 , and R_5 or any adjacent R_6 , R_7 , R_8 , and R_9 are fused together to

form a five-membered or six-membered heteroaryl or six-membered aryl ring moiety,
wherein said five-membered or six-membered heteroaryl or six-membered aryl ring
comprises two carbon atoms of quinoxaline ring to which R_3 , R_4 , and R_5 or R_6 , R_7 , R_8 , and R_9
are attached; and


(f) R_{11} and R_{12} are independently selected from the group consisting of

(i) hydrogen;

(ii) saturated or unsaturated alkyl; and

(g) Z' is carbon, oxygen, sulfur, or nitrogen and R_{13} and R_{14} taken together form a
five-membered or six-membered heteroaryl ring with Z' as a ring member.

11. (Amended) The method of claim 1, wherein said quinoxaline-based compound has the formula set forth in structure I, II, or III:



wherein:

(a) Z is oxygen, NX_1 , or sulfur, where X_1 is selected from the group consisting of hydrogen, saturated or unsaturated alkyl;

(b) n is 0, 1, 2;

(c) A_1 , A_2 , A_3 , A_4 , and A_5 , ~~and A_6~~ are independently selected from the group consisting of carbon, nitrogen, oxygen, and sulfur,

provided that if any of A_1 , A_2 , A_3 , A_4 and A_5 is nitrogen, oxygen, or sulfur, said A_1 , A_2 , A_3 , A_4 and A_5 is not substituted with R_6 , R_7 , R_8 or R_9 ;

(d) R_1 and R_2 are independently selected from the group consisting of:

(i) hydrogen;

(ii) saturated or unsaturated alkyl;

(iii) NX_2X_3 , where X_2 and X_3 are independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl; ~~and~~

(iv) halogen or trihalomethyl; and

(v) five-membered or six-membered heteroaryl ring moiety;

(e) R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , and R_9 , ~~and R_{10}~~ are independently selected from the group consisting of:

(i) hydrogen;

(ii) saturated or unsaturated alkyl;

(iii) NX_4X_5 , where X_4 and X_5 are independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl; ~~and~~

(iv) halogen or trihalomethyl; and

(v) $-OX_7$, where X_7 is selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and a five-membered or six-membered aryl or heteroaryl ring moiety;

(f) any adjacent R_3 , R_4 , and R_5 or any adjacent R_6 , R_7 , R_8 , and R_9 , ~~and R_{10}~~ are fused together to form a five-membered or six-membered aryl or heteroaryl ring moiety, wherein said five-membered or six-membered aryl or six-membered heteroaryl ring comprises two carbon atoms of the quinazoline ring to which R_3 , R_4 , and R_5 or R_6 , R_7 , R_8 , and R_9 are attached;

(g) R_{11} and R_{12} are independently selected from the group consisting of



(i) hydrogen;

(ii) saturated or unsaturated alkyl; and

(h) Z' is carbon, oxygen, sulfur, or nitrogen and R_{13} and R_{14} taken together form a five-membered or six-membered heteroaryl ring with Z' as a ring member, wherein said ring

is optionally substituted with one, two, or three alkyl, halogen, trihalomethyl, carboxylate, and ester moieties.

12. (Amended) The method of claim 1, wherein said quinazoline-based compound has the formula set forth in formula IV or V:





















wherein:


- (a) Z is oxygen or sulfur;
- (b) n is 0 or 1;
- (c) R₁ and R₂ are independently selected from the group consisting of:
 - (i) hydrogen;
 - (ii) NX₁X₂, where X₁ and X₂ are independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl;
 - (iii) benzyl;
- (d) R₃, R₄, and R₅ are independently selected from the group consisting of:
 - (i) hydrogen; and
 - (ii) saturated or unsaturated alkyl;
 - (iii) NX₃X₄, where X₃ and X₄ are independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl; and
- ~~— (e) R₆, R₇, R₈, R₉, and R₁₀ are independently selected from the group consisting of~~

- (i) hydrogen;
- (ii) saturated or unsaturated alkyl;
- (iii) NX_5X_6 , where X_5 and X_6 are independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl; and
- (iv) halogen or trihalomethyl;
- (v) $\text{C}(\text{X}_7)_3$, where X_7 is selected from the group consisting of fluorine, chlorine, bromine, and iodine; and
- (vi) methoxy;
- (fe) R_{11} and R_{12} hydrogen; and
- (gf) Z' is nitrogen and R_{13} and R_{14} taken together form a five-membered heteroaryl ring.


16. (Amended) The method of claim 1, wherein said quinazoline-based compound is selected from the group consisting of:







17. (Amended) A method of preventing or treating an abnormal condition in an organism, comprising the step of administering a quinazoline-based compound of formula I, H₇, or III to said organism:



wherein:

(a) Z is oxygen, NX₁, or sulfur, where X₁ is selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and five-membered or six-membered heteroaryl or six-membered aryl ring moieties;

(b) n is 0, 1, 2, 3, or 4;

(c) A₁, A₂, A₃, A₄, A₅, and A₆ are independently selected from the group consisting of carbon, nitrogen, oxygen, and sulfur, provided that if any of A₁, A₂, A₃, A₄ and A₅ is nitrogen, oxygen, or sulfur, said A₁, A₂, A₃, A₄ and A₅ is not substituted with R₆, R₇, R₈ or R₉;

(d) R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, and R₉, and R₁₀ are independently selected from the group consisting of:

(i) hydrogen;

(ii) saturated or unsaturated alkyl;

(iii) NX_2X_3 , where X_2 and X_3 are independently selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and five-membered or six-membered heteroaryl or six-membered aryl ring moieties;

(iv) halogen or trihalomethyl;

(v) a ketone of formula $-CO-X_4$, where X_4 is selected from the group consisting of hydrogen, alkyl, and five-membered or six-membered heteroaryl or six-membered aryl ring moieties;

(vi) a carboxylic acid of formula $-(X_5)_{n5}-COOH$ or ester of formula $-(X_6)_{n6}-COOX_7$, where X_5 , X_6 , and X_7 are independently selected from the group consisting of alkyl and five-membered or six-membered heteroaryl or six-membered aryl ring moieties and where $n5$ and $n6$ are each independently 0 or 1;

(vii) an alcohol of formula $-(X_8)_{n8}-OH$ or an alkoxy moiety of formula $-(X_8)_{n8}-OX_9$, where X_8 and X_9 are independently selected from the group consisting of alkyl and five-membered or six-membered heteroaryl or six-membered aryl ring moieties and where $n8$ is 0 or 1, and where said ring moieties are optionally substituted with one or more substituents selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, and ester;

(viii) $-NHCOX_{10}$, where X_{10} is selected from the group consisting of alkyl, hydroxyl, and five-membered or six-membered heteroaryl or six-membered aryl ring moieties, wherein said ring moieties are optionally substituted with one or more substituents selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, and ester;

(ix) $-SO_2NX_{11}X_{12}$, where X_{11} and X_{12} are selected from the group consisting of hydrogen, alkyl, and five-membered or six-membered heteroaryl or six-membered aryl ring moieties; and

(x) a five-membered or six-membered heteroaryl or six-membered aryl ring moiety optionally substituted with one or more substituents selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, and ester moieties;

(e) any adjacent R_3 , R_4 , and R_5 or any adjacent R_6 , R_7 , R_8 , and R_9 are fused together to form a five-membered or six-membered heteroaryl or six-membered aryl ring moiety, wherein said five-membered or six-membered heteroaryl or six-membered aryl ring comprises two carbon atoms of the quinoxaline ring to which R_3 , R_4 , and R_5 or R_6 , R_7 , R_8 , and R_9 are attached; and




(f) R_{11} and R_{12} are independently selected from the group consisting of

(i) hydrogen;

(ii) saturated or unsaturated alkyl; and

(g) Z' is carbon, oxygen, sulfur, or nitrogen and R₁₃ and R₁₄ taken together form a five-membered or six-membered heteroaryl ring with Z' as a ring member.

26. (Amended) A quinazoline compound having the formula I, II, or III:



wherein:

(i) Z is oxygen, NX₁, or sulfur, where X₁ is selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and five-membered or six-membered heteroaryl or six-membered aryl ring moieties;

(ii) n is 0, 1, 2, 3, or 4;

(iii) A₁, A₂, A₃, A₄, and A₅, and A₆ are independently selected from the group consisting of carbon, nitrogen, oxygen, and sulfur,

provided that if any of A₁, A₂, A₃, A₄ and A₅ is nitrogen, oxygen, or sulfur, said A₁, A₂, A₃, A₄ and A₅ is not substituted with R₆, R₇, R₈ or R₉;

(iv) R₁ and R₂ are independently selected from the group consisting of:

(a) hydrogen;

(b) saturated or unsaturated alkyl;

(c) NX₂X₃, where X₂ and X₃ are independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl; ~~and~~

(d) halogen or trihalomethyl; and

(e) five-membered or six-membered heteroaryl ring moiety;

(v) $R_3, R_4, R_5, R_6, R_7, R_8, \underline{R_9}$ and R_{10} are independently selected from the group consisting of:

(a) hydrogen, ~~provided that at least one of $R_3, R_4, R_5, R_6, R_7, R_8, R_9$ and R_{10} is a non-hydrogen moiety if R_2 is NH_2 ;~~

(b) saturated or unsaturated alkyl, ~~wherein said R_8 is not methyl when R_2 is NH_2 and when $n = 1$;~~

(c) $\text{NX}_{132}\text{X}_{143}$, where X_{132} and X_{143} are independently selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and five-membered or six-membered aryl or heteroaryl ring moieties; ~~and~~

(d) halogen or trihalomethyl, ~~wherein said R_8 is not chlorine or fluorine when R_2 is NH_2 and when $n = 1$;~~

(e) a ketone of formula $-\text{CO}-\text{X}_4$, where X_4 is selected from the group consisting of hydrogen, alkyl, and five-membered or six-membered heteroaryl or six-membered aryl ring moieties;

(f) a carboxylic acid of formula $-(\text{X}_5)_{n5}-\text{COOH}$ or ester of formula $-(\text{X}_6)_{n6}-\text{COOX}_7$, where X_5, X_6 , and X_7 are independently selected from the group consisting of alkyl and five-membered or six-membered heteroaryl or six-membered aryl ring moieties and where $n5$ and $n6$ are each independently 0 or 1;

(g) an alcohol of formula $-(\text{X}_8)_{n8}-\text{OH}$ or an alkoxy moiety of formula $-(\text{X}_8)_{n8}-\text{OX}_9$, where X_8 and X_9 are independently selected from the group consisting of alkyl and five-membered or six-membered heteroaryl or six-membered aryl ring moieties and where $n8$ is 0 or 1, and where said ring moieties are optionally substituted with one or more substituents selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, and ester;

(h) $-\text{NHCOX}_{10}$, where X_{10} is selected from the group consisting of alkyl, hydroxyl, and five-membered or six-membered heteroaryl or six-membered aryl ring moieties, wherein said ring moieties are optionally substituted with one or more substituents selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, and ester;

(i) $-\text{SO}_2\text{NX}_{11}\text{X}_{12}$, where X_{11} and X_{12} are selected from the group consisting of hydrogen, alkyl, and five-membered or six-membered heteroaryl or six-membered aryl ring moieties; and

(j) a five-membered or six-membered heteroaryl or six-membered aryl ring moiety optionally substituted with one or more substituents selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, and ester moieties;

(vi) any adjacent R₃, R₄, and R₅ or any adjacent R₆, R₇, R₈, and R₉ are fused together to form a five-membered or six-membered heteroaryl or six-membered aryl ring moiety, wherein said five-membered or six-membered heteroaryl or six-membered aryl ring comprises two carbon atoms of the quinoxaline ring to which R₃, R₄, and R₅ or R₆, R₇, R₈, and R₉ are attached;




(vii) R₁₁ and R₁₂ are independently selected from the group consisting of

(i) hydrogen;

(ii) saturated or unsaturated alkyl; and

(viii) Z' is carbon, oxygen, sulfur, or nitrogen and R₁₃ and R₁₄ taken together form a five-membered or six-membered heteroaryl ring with Z' as a ring member.

27. (Amended) A quinoxaline compound having the formula I, II, or III:



wherein:

(a) Z is oxygen, NX₁, or sulfur, where X₁ is selected from the group consisting of hydrogen, saturated or unsaturated alkyl;



(b) n is 0, 1, 2;

(c) A₁, A₂, A₃, A₄, and A₅ and A₆ are independently selected from the group consisting of carbon, nitrogen, oxygen, and sulfur,

provided that if any of A₁, A₂, A₃, A₄ and A₅ is nitrogen, oxygen, or sulfur, said A₁, A₂, A₃, A₄ and A₅ is not substituted with R₆, R₇, R₈ or R₉;

- (d) R_1 and R_2 are independently selected from the group consisting of:
- (i) hydrogen;
 - (ii) saturated or unsaturated alkyl;
 - (iii) NX_2X_3 , where X_2 and X_3 are independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl; ~~and~~
 - (iv) halogen or trihalomethyl; ~~and~~
 - (v) five-membered or six-membered heteroaryl ring moiety;
- (e) R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , ~~and R_9 and R_{10}~~ are independently selected from the group consisting of:
- (i) ~~hydrogen, provided that at least one of R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 and R_{10} is a non hydrogen moiety if R_2 is NH_2 ;~~
 - (ii) ~~saturated or unsaturated alkyl, wherein said R_8 is not methyl when R_2 is NH_2 and when $n = 1$;~~
 - (iii) NX_4X_5 , where X_4 and X_5 are independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl; ~~and~~
 - (iv) ~~halogen or trihalomethyl, wherein said R_8 is not chlorine or fluorine when R_2 is NH_2 and when $n = 1$;~~
 - (v) $C(X_6)_3$, where X_6 is selected from the group consisting of fluorine, chlorine, bromine and iodine;
 - (vi) $-OX_7$, where X_7 is selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and a five-membered or six-membered aryl or heteroaryl ring moiety;
- (f) any adjacent R_3 , R_4 , and R_5 or any adjacent R_6 , R_7 , R_8 , ~~and R_9 and R_{10}~~ are fused together to form a five-membered or six-membered aryl or heteroaryl ring moiety, wherein said five-membered or six-membered aryl or six-membered heteroaryl ring comprises two carbon atoms of the quinazoline ring to which R_3 , R_4 , and R_5 or R_6 , R_7 , R_8 , and R_9 are attached;
- (g) R_{11} and R_{12} are independently selected from the group consisting of
- (i) hydrogen;
 - (ii) saturated or unsaturated alkyl; and
- (h) Z' is carbon, oxygen, sulfur, or nitrogen and R_{13} and R_{14} taken together form a five-membered or six-membered heteroaryl ring with Z' as a ring member, wherein said ring is optionally substituted with one, two, or three alkyl, halogen, trihalomethyl, carboxylate, and ester moieties.

28. (Amended) A quinazoline compound having the structure set forth in formula IV or V:










wherein:

- (a) Z is oxygen or sulfur;
- (b) n is 0 or 1;
- (c) R₁ and R₂ are independently selected from the group consisting of:
 - (i) hydrogen;
 - (ii) NX₁X₂, where X₁ and X₂ are independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl;
 - (iii) benzyl;
- (d) R₃, R₄, and R₅ are independently selected from the group consisting of:
 - (i) hydrogen; ~~and~~
 - (ii) saturated or unsaturated alkyl; and
 - (iii) NX₃X₄, where X₃ and X₄ are independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl;
- ~~(e) R₃, R₄, R₅, R₆, R₇, R₈, R₉, and R₁₀ are independently selected from the group consisting of~~


- ~~—— (i) hydrogen provided that at least one of $R_3, R_4, R_5, R_6, R_7, R_8, R_9,$ and R_{10} is a non-hydrogen moiety if R_2 is NH_2 ;~~
~~—— (ii) saturated or unsaturated alkyl, wherein said R_8 is not methyl when R_2 is NH_2 and when $n=1$;~~
~~—— (iii) NX_5X_6 , where X_5 and X_6 are independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl; and~~
~~—— (iv) halogen or trihalomethyl, wherein said R_8 is not chlorine or fluorine when R_2 is NH_2 and when $n=1$;~~
~~—— (v) $\text{C}(\text{X}_7)_3$, where X_7 is selected from the group consisting of fluorine, chlorine, bromine, and iodine; and~~
~~—— (vi) methoxy;~~
 (f) R_{11} and R_{12} hydrogen; and
 (g) Z' is nitrogen and R_{13} and R_{14} taken together form a five-membered heteroaryl ring.

32. (Amended) A quinazoline compound which is selected from the group consisting of:







A-7




A-9




A-11




A-13




A-15




A-8




A-10






A-12



A-14




A-16





33. (Amended) A pharmaceutical composition comprising a quinazoline compound of any one of claims ~~26-32~~ 26, 27, 31 or 32 or salt thereof, and a physiologically acceptable carrier or diluent.

34. (Amended) A method for synthesizing a compound of claim 26, comprising the steps of:

(a) reacting a first reactant with a second reactant to yield said compound, wherein said first reactant has a structure of formula XI:



and wherein said second structure has a structure of formula (XII) or (XIII):



wherein,

- (a) Z is oxygen or sulfur;
- (b) n is 0, 1, 2, 3, or 4;
- (c) A₁, A₂, A₃, A₄, and A₅ ~~and A₆~~ are independently selected from the group consisting of carbon, nitrogen, oxygen, and sulfur,
provided that if any of A₁, A₂, A₃, A₄ and A₅ is nitrogen, oxygen, or sulfur,
said A₁, A₂, A₃, A₄ and A₅ is not substituted with R₆, R₇, R₈ or R₉;
- (d) R₁ and R₂ are independently selected from the group consisting of:
 - (i) hydrogen;
 - (ii) saturated or unsaturated alkyl;
 - (iii) NX₂X₃, where X₂ and X₃ are independently selected from the group consisting of hydrogen, saturated or unsaturated alkyl, ~~and~~
 (iv) halogen or trihalomethyl; and
 (v) five-membered or six-membered heteroaryl ring moiety;
- (e) R₃, R₄, R₅, R₆, R₇, R₈, and R₉ ~~and R₁₀~~ are independently selected from the group consisting of:
 - (i) ~~hydrogen, provide that at least one of R₃, R₄, R₅, R₆, R₇, R₈, R₉ and R₁₀ is a non hydrogen moiety if R₂ is NH₂;~~
 - (ii) saturated or unsaturated alkyl, ~~wherein said R₈ is not methyl when R₂ is NH₂ and when n=1;~~
 - (iii) NX₂₁₃X₁₄₃, where X₁₃₂ and X₁₄₃ are independently selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and five-membered or six-membered aryl or heteroaryl ring moieties;
 - (iv) ~~halogen or trihalomethyl, wherein said R₈ is not chlorine or fluorine when R₂ is NH₂ and when n=1;~~
 - (v) a ketone of formula -CO-X₄, where X₄ is selected from the group consisting of hydrogen, alkyl, and five-membered or six-membered heteroaryl or six-membered aryl ring moieties;
 - (vi) a carboxylic acid of formula -(X₅)_{n5}-COOH or ester of formula -(X₆)_{n6}-COOX₇, where X₅, X₆, and X₇ and are independently selected from the group consisting of alkyl and five-membered or six-membered heteroaryl or six-membered aryl ring moieties and where n5 and n6 are ~~is~~ 0 or 1;
 - (vii) an alcohol of formula -(X₈)_{n8}-OH or an alkoxy moiety of formula -(X₈)_{n8}-OX₉, where X₈ and X₉ are independently selected from the group consisting of alkyl

and five-membered or six-membered heteroaryl or six-membered aryl ring moieties and where n_8 is 0 or 1, and where said ring moieties are optionally substituted with one or more substituents selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, and ester;

(viii) -NHCOX_{10} , where X_{10} is selected from the group consisting of alkyl, hydroxyl, and five-membered or six-membered heteroaryl or six-membered aryl ring moieties, wherein said ring moieties are optionally substituted with one or more substituents selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, and ester;

(ix) $\text{-SO}_2\text{NX}_{11}\text{X}_{12}$, where X_{11} and X_{12} are selected from the group consisting of hydrogen, alkyl, and five-membered or six-membered heteroaryl or six-membered aryl ring moieties; and

(x) a five-membered or six-membered heteroaryl or six-membered aryl ring moiety optionally substituted with one or more substituents selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, and ester moieties;

(f) any adjacent R_3 , R_4 , and R_5 or any adjacent R_6 , R_7 , R_8 , and R_9 , ~~and R_{10}~~ are fused together to form a five-membered or six-membered aryl or heteroaryl ring wherein said five-membered or six-membered aryl or heteroaryl ring comprises two carbon atoms of the quinazoline ring to which R_3 , R_4 , and R_5 or R_6 , R_7 , R_8 , and R_9 are attached;

(g) R_{11} and R_{12} are independently selected from the group consisting of

(i) hydrogen; and

(ii) saturated or unsaturated alkyl; and

(b) collecting a precipitate comprising said compound.

37. (Amended) The method of ~~any one of claims~~ claim 34, ~~35, or 36~~ wherein said first reactant and said second reactant are mixed in one or more solvents selected from the group consisting of dimethyl sulfoxide, potassium tert-butoxide, and sodium hydride.